September 28, 2016 1:35 PM ET

Healthcare Equipment and Supplies

Company Overview of Veracyte, Inc.

Company Overview

Veracyte, Inc. operates as a molecular diagnostics company. It develops and delivers molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company also offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. In addition, it engages in developing the Percepta Bronchial Genomic Classifier, a gene expression test to identify patients with lung nodules who are at low risk of cancer following...

6000 Shoreline Court

Suite 300

South San Francisco, CA 94080

United States

Founded in 2006

192 Employees



Key Executives for Veracyte, Inc.

Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee
Age: 58
Total Annual Compensation: $457.0K
Chief Financial Officer
Age: 56
Total Annual Compensation: $321.0K
Chief Operating Officer
Age: 47
Total Annual Compensation: $383.0K
Compensation as of Fiscal Year 2015.

Veracyte, Inc. Key Developments

Veracyte, Inc Announces Data Demonstrating Potential to Enhance Afirma Gene Expression Classifier Using an RNA Sequencing Platform

Veracyte, Inc. announced new data suggesting the potential to enhance the performance of the Afirma Gene Expression Classifier in thyroid cancer diagnosis by combining the test's proven RNA expression-based capabilities with gene variant and fusion information, all on a single, robust RNA sequencing platform. Such enhancements could help to further reduce the number of patients who undergo unnecessary surgery when their thyroid nodules are not clearly benign or cancerous (i.e., indeterminate) following routine cytopathology evaluation. The company scientists presented the findings in a poster session at the 86th Annual Meeting of the American Thyroid Association, being held in Denver through September 25. Six additional posters are being presented at the ATA meeting by external researchers and underscore the Afirma GEC's role as a new standard of care in thyroid cancer diagnosis. In the company study, company researchers used RNA from 88 thyroid nodule patient samples for which a surgical pathology diagnosis was known to train (with 58 samples) and test (with 30 samples) an enhanced version of the Afirma GEC. Using advanced machine-learning techniques, the company leveraged an RNA sequencing platform to combine the genomic test's RNA gene expression-based algorithm with gene variant and fusion information. The result was an enriched classifier that yielded an overall area under curve (AUC) of 0.88, with a sensitivity of 93% and a specificity of 80%.

Veracyte, Inc.(NasdaqGM:VCYT) dropped from S&P Global BMI Index

Veracyte, Inc.(NasdaqGM:VCYT) dropped from S&P Global BMI Index

Veracyte, Inc. - Special Call

To discuss the draft Medicare coverage for the Percepta classifier, the clinical and market landscape for the test and the company's commercialization plans.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Private Placement
March 25, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Veracyte, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at